Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAN-001
- Development stage
- Phase 2
- Lead developer
- Zelira Therapeutics
- Modality
- Small Molecules
01
Overview
**CAN-001** is a chemical drug initially developed by Zelira Therapeutics Ltd. for **chemotherapy-induced nausea and vomiting (CINV)**, with its global highest R&D status listed as Pending in the therapeutic area of Other Diseases. No specific mechanism of action, targets, or active indications are detailed in available data, and no ongoing clinical trials or further development updates are identified.[1]
Beyond the preview
Go deeper on CAN-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAN-001.